National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 4366-4367 [2017-00581]
Download as PDF
<![CDATA[
asabaliauskas on DSK3SPTVN1PROD with NOTICES
4366
Federal Register / Vol. 82, No. 9 / Friday, January 13, 2017 / Notices
NIH_Guidelines.html), these
experiments can proceed only after they
are reviewed by the NIH Recombinant
DNA Advisory Committee (RAC) and
specifically approved by the NIH
Director as Major Actions. This proposal
was discussed at the December 4, 2015,
RAC meeting. The proposal was
published in the Federal Register on
December 29, 2015, (80 FR 81346) with
a request for public comment; one
comment was received. This notice
announces the final NIH action
regarding this proposal.
FOR FURTHER INFORMATION CONTACT: If
you have questions, or require
additional background information
about this action, please contact the NIH
by email at SciencePolicy@od.nih.gov,
or by telephone at 301–496–9838 and
reference this notice.
SUPPLEMENTARY INFORMATION: This final
action does not allow an investigator at
the University of Chicago to transfer
chloramphenicol resistance to three
different Rickettsia species: Rickettsia
typhi, rickettsii, and felis. The
investigator also proposed to transfer
chloramphenicol resistance to a fourth
Rickettsia species, R. conorii. Transfer of
chloramphenicol resistance to R. conorii
was previously approved by the NIH
Director as a Major Action (see 73 FR
32719) and therefore did not need to be
reviewed and approved under Section
III–A–1–a of the NIH Guidelines. Thus,
the University of Chicago investigator
was allowed to proceed with the
transfer of chloramphenicol resistance
to R. conorii under Section III–B–2 of
the NIH Guidelines.
The proposal to transfer
chloramphenicol resistance to R. typhi,
rickettsii, and felis was discussed with
a working group of the RAC via a
teleconference call on October 22, 2015.
The recommendations of this group
were presented to and discussed with
the RAC at its December 4, 2015,
meeting. At the March 8, 2016, meeting,
the RAC continued the discussion
which included consideration of the one
comment received to the December 29,
2015, notice and unanimously
recommended (by a vote of 11 in favor,
none opposed, and no abstentions) that
the transfer of chloramphenicol
resistance to R. typhi, rickettsii, and felis
should not be allowed to proceed. On
August 23, 2016, the NIH Director
disapproved the proposal to transfer
chloramphenicol resistance to R. typhi,
rickettsii, and felis.
Dated: January 6, 2017.
Francis S. Collins,
Director, National Institutes of Health.
[FR Doc. 2017–00766 Filed 1–12–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:06 Jan 12, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Monoclonal Antibodies That Neutralize
Norovirus
Description of Technology: Vaccines
and therapies to prevent and treat
Norovirus infections do not exist,
despite the worldwide prevalence of
Norovirus infections. Outbreaks of
human gastroenteritis attributable to
Norovirus commonly occur in group
setting, such as hospitals, nursing
homes, schools, dormitories, cruise
ships and military barracks. This
technology relates to chimpanzeehuman chimeric monoclonal antibodies,
which specifically bind to Norovirus
and have therapeutic potential. The
antibodies that were tested in a primate
model of infection have shown
protection against Norovirus. These
Norovirus antibodies may have
application as immunoprophylaxis to
protect individuals from infections or as
a possible treatment for infected
individuals, or can be used to develop
a diagnostic for detection of norovirus
infections.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Therapeutics
• Diagnostics
Competitive Advantages:
• There are currently no vaccines or
therapeutics available against
Norovirus infections
Development Stage:
• In vivo data available (animal)
Inventors: Zhaochun Chen, Robert H.
Purcell, Lisbeth Kim Green, Stanislav
Sosnovtsev, Karin Bok (all from NIAID).
Publications: Chen Z, et al.,
Development of Norwalk virus-specific
monoclonal antibodies with therapeutic
potential for the treatment of Norwalk
virus gastroenteritis, J Virol. 2013 Sep;
87(17):9547–57. [PMID 23785216].
Intellectual Property: HHS Reference
No. E–226–2011/0—U.S. Provisional
Application No. 61/763,879, filed
February 12, 2013; PCT Application No.
PCT/US2014/015809, filed February 11,
2014; European Application No.
14706239.2, filed August 5, 2015
(pending); U.S. Application No. 14/
767,274, filed August 11, 2015
(allowed); and U.S. Application No. 15/
359,438, filed November 22, 2016
(pending).
Licensing Contact: Dr. Jenish Patel,
240–669–2894; Jenish.Patel@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize for development of a
therapeutic or a diagnostic for Norovirus
infections. For collaboration
opportunities, please contact Dr. Jenish
Patel, 240–669–2894; Jenish.Patel@
nih.gov.
Dated: January 9, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–00735 Filed 1–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
E:\FR\FM\13JAN1.SGM
13JAN1
Federal Register / Vol. 82, No. 9 / Friday, January 13, 2017 / Notices
asabaliauskas on DSK3SPTVN1PROD with NOTICES
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity Research.
Date: January 26, 2017.
Time: 1:30 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; R13 Conference
Grant Applications.
Date: February 23, 2017.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Jian Yang, Ph.D., Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
7111, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7799, yangj@
extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–16–126: High
Impact, Interdisciplinary Science in NIDDK
Research Areas (RC2)—Renal Repair and
Regeneration.
Date: March 1, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894
begumn@niddk.nih.gov.
VerDate Sep<11>2014
19:06 Jan 12, 2017
Jkt 241001
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; RFA–DK–16–011:
Central Primary Reference Laboratory for
HbA1C and C-Peptide Measurements (UC4).
Date: March 2, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, NAtional Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: January 9, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–00581 Filed 1–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: NIGMS Initial Review
Group; Training and Workforce Development
Subcommittee—C, To Review R25 Research
Training Grant Applications.
Date: March 9–10, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Marriott Wardman Park,
2660 Woodley Road NW., Washington, DC
20008.
Contact Person: Lee Warren Slice, Ph.D.,
Scientific Review Officer, Office of Scientific
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
4367
Review, National Institute of General Medical
Sciences, National Institutes of Health, 1
Democracy Plaza, 6701 Democracy Blvd.,
Room 1068, Bethesda, MD 20892, 301–435–
0807, slicelw@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
Dated: January 9, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–00582 Filed 1–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; AITRC Independent SEP.
Date: February 13, 2017.
Time: 2:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room #3G41B, National Institutes
of Health/NIAID, 5601 Fishers Lane, MSC
9823, Bethesda, MD 20892–9823, (240) 669–
5068, zhuqing.li@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34, R01, U01).
Date: February 14, 2017.
E:\FR\FM\13JAN1.SGM
13JAN1
]]>Agencies
[Federal Register Volume 82, Number 9 (Friday, January 13, 2017)]
[Notices]
[Pages 4366-4367]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-00581]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
[[Page 4367]]
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Time-Sensitive Obesity
Research.
Date: January 26, 2017.
Time: 1:30 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Michele L. Barnard, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301)
594-8898, barnardm@extra.niddk.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; R13 Conference Grant
Applications.
Date: February 23, 2017.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Jian Yang, Ph.D., Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 7111,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7799,
yangj@extra.niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; PAR-16-126: High Impact,
Interdisciplinary Science in NIDDK Research Areas (RC2)--Renal
Repair and Regeneration.
Date: March 1, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Najma Begum, Ph.D., Scientific Review Officer,
Review Branch, DEA, NIDDK, National institutes of Health, Room 7349,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8894
begumn@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; RFA-DK-16-011: Central
Primary Reference Laboratory for HbA1C and C-Peptide Measurements
(UC4).
Date: March 2, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Najma Begum, Ph.D., Scientific Review Officer,
Review Branch, DEA, NIDDK, NAtional Institutes of Health, Room 7349,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8894,
begumn@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: January 9, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-00581 Filed 1-12-17; 8:45 am]
BILLING CODE 4140-01-P
